November 25, 2025: new publication on Pancreatic cancer
Léon Raymakers, Lois A. Daamen, Martijn P. W. Intven, Jeanette H. W. Leusen, Patricia A. Olofsen, Anja van de Stolpe, Reinier A. P. Raymakers. Quantification of Signal Transduction Pathway Activity in Pancreatic Ductal Adenocarcinoma. Int. J. Mol. Sci. 2025, 26(23), 11385; https://doi.org/10.3390/ijms262311385
DCDC-Tx and BioDetection Systems found Metamorphosis-Tx to develop cancer differentiation therapy
December 20, 2023. Metamorphosis Tx has been founded as a subsidiary of DCDC-Tx. BioDetection Systems (BDS) is co-founder of Metamorphosis. Metamorphosis is dedicated to development of cancer differentiation therapy. DCDC Tx and BioDetection Systems make their proprietary technologies available to Metamorphosis. The proprietary CALUX reporter cell line technology of BDS complements the STAP-STP technology of DCDC-Tx. Combined use of STAP and CALUX Signal Transduction Pathway technologies enables Metamorphosis to develop cancer differentiation therapies using both existing drugs (drug repurposing) and new drug discovery. Initial focus is on highly malignant glioblastoma multiforme (GBM) and pediatric DIPG (diffuse Intrinsic Pontine Glioma), ovarian cancer and aggressive types of breast cancer.